PE Tech Report


Like this article?

Sign up to our free newsletter

Arsenal Capital acquires Synchrogenix

Private equity firm Arsenal Capital Partners has acquired Synchrogenix, a regulatory writing and related services firm. 

Synchrogenix provides services to pharmaceutical, biotechnology, and medical device companies worldwide. 
Concurrent with the transaction, Synchrogenix will be merged into Certara, a global technology-enabled drug development and drug safety consultancy acquired by Arsenal this past December. 
Stephen McLean, a partner at Arsenal and co-head of the firm's healthcare group, says: "Pharmaceutical companies are looking for greater value and increased synergies from their outsourcing partners. Adding the complementary services Synchrogenix offers to the Certara portfolio will allow Certara to provide its preclinical and clinical pharmacology customers with end-to-end drug development consulting and writing services, including preparation of regulatory submissions such as the Biologic License Application, Investigational New Drug and New Drug Applications."
Donald Deieso, operating partner at Arsenal and co-head of the healthcare group, says: "We were attracted to Synchrogenix by the quality of its work, its outstanding reputation and the global network of regulatory experts that it has developed. By combining the most sophisticated regulatory professional organisation with the world's leading computational drug development capabilities, we believe that Certara can continue to enable our clients to improve the pace of efficacious drug development for the benefit of patients around the world."
Certara provides its global pharmaceutical and biotechnology customers with scientific informatics and analytics, including molecular modelling, population-based simulations, pharmacokinetic analyses and clinical trial simulations. Certara has more than 225 employees located at offices in the US, UK, Canada, and Japan. 
Based in Wilmington, Delaware, Synchrogenix is the largest independent regulatory-writing CRO in the world. It has more than 50 permanent regulatory writers and editors on staff, located in seven offices in North America, Europe, and Asia. The company provides pre-clinical, clinical, CMC and drug safety writing, and global regulatory submission services.
"Having worked with our talented staff to build Synchrogenix from the ground up, I was looking for a like-minded company that shared our strong work ethic and focus on excellent customer service and high-quality results. We have found a great match in Arsenal and Certara, and I look forward to expanding the range of services that we offer to all of our customers," says Synchrogenix CEO Ellen Barrosse, who will remain the CEO of Synchrogenix following the transaction.

Like this article? Sign up to our free newsletter